Text Size

Surgery for Intravenous Leiomyomatosis (SIVL)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Li Yang, General Hospital of Beijing PLA Military Region
ClinicalTrials.gov Identifier:
NCT01707862
First received: October 14, 2012
Last updated: October 15, 2012
Last verified: October 2012
History of Changes
  Purpose

Intravenous leiomyomatosis (IVL) with intracardiac extension is a rare benign smooth muscle tumor. Reviewing literature, intracardiac extension of the IVL has been reported in at least 70 cases. Most are individual case reports. Surgical experience is not much. However, different opinion of surgical strategies remain controversial. The purpose of this report is to describe our experience of surgical management for the IVL with intracardiac extension.


Condition
Leiomyomatosis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Surgical Management of Intravenous Leiomyomatosis With Intracardiac Extension: Our Experience and Outcomes

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by General Hospital of Beijing PLA Military Region:

Enrollment: 6
Study Start Date: March 1997
Study Completion Date: October 2012
Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
Detailed Description:

All patients underwent surgical management. Clinical data were obtained from medical reports. Following-up was made through email and telephone.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

From March 1997 to June 2011, 6 women patients were admitted to our hospital with intravenous leiomyomatosis with intracardiac extension.

Criteria

Inclusion Criteria:

  • Age more than 18 years.
  • Tumor markers were all within normal limits.
  • Patients underwent surgical management.
  • Patients were followed-up for more than 12 months.

Exclusion Criteria:

-Tumor markers were all within abnormal limits

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01707862

Locations
China
Institute of Cardiovascular Disease
Beijing, China
Sponsors and Collaborators
Li Yang
Investigators
Principal Investigator: Genetal Hospital Beijing Military Region, First class Institute of Cardiovascular Disease
  More Information

No publications provided

Responsible Party: Li Yang, Doctor, General Hospital of Beijing PLA Military Region
ClinicalTrials.gov Identifier: NCT01707862     History of Changes
Other Study ID Numbers: GHBeijing-20121012
Study First Received: October 14, 2012
Last Updated: October 15, 2012
Health Authority: China: Food and Drug Administration

Keywords provided by General Hospital of Beijing PLA Military Region:
Intravenous leiomyomatosis
Surgery
Smooth muscle tumor

Additional relevant MeSH terms:
Leiomyomatosis
Leiomyoma
Neoplasms, Muscle Tissue
 Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on May 23, 2013